GEMoaB

Feb 10, 2021

GEMoaB Announces Presentation of Translational Data From Ongoing Phase I Clinical Study of Their Lead Asset UniCAR-T-CD123 in Relapsed/Refractory AML at the Upcoming 2021 AACR Annual Meeting

Feb 03, 2021

GEMoaB Announces UniCAR-T-CD123 Data from its Ongoing Phase I Study in Patients with Relapsed/Refractory AML (rrAML) to be Presented at Virtual 3rd EHA-EBMT European CAR T-Cell Meeting

Jan 07, 2021

GEMoaB Announces Clinical Data Presentations on Their Lead Asset UniCAR-T-CD123 in relapsed/refractory AML at the Upcoming EHA-EBMT 3rd European CAR T-Cell Meeting

Dec 03, 2020

Initiation of First UniCAR Cellular Immunotherapy Study in Advanced Solid Tumors

Jul 20, 2020

GEMoaB and Intellia Therapeutics Enter into Research Collaboration and Licensing Agreement on Next-Generation Cellular Immunotherapy Based on Proprietary RevCAR and CRISPR/Cas9 Genome Editing Platforms

May 15, 2020

GEMoaB Announces Data Presentations Supporting Key Features of Its UniCAR Platform At the Upcoming American Association for Cancer Research (AACR) Meeting II

Mar 17, 2020

GEMoaB Announces Publication of Pre-Clinical Proof-of-Concept Data on UniCAR-modified Off-the-shelf Natural Killer Cells in 'Nature Scientific Reports'

Mar 09, 2020

GEMoaB Announces First Patient Apheresed in a Phase IA Study With Lead Product Candidate From Rapidly Switchable Universal CAR-T Platform (UniCAR) in CD123 Positive Relapsed/Refractory Acute Leukemias